---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-002514"
form_type: "8-K"
ticker: "CVRX"
cik: "0001235912"
company_name: "CVRx, Inc."
filed_at: "2022-01-10T23:59:59+00:00"
generated_at: "2026-06-27T19:13:48.685649+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CVRx preliminary Q4 rev $3.6-3.7M (+71-77% YoY); FY2021 rev $13.0-13.1M (+113-116% YoY); FY2022 guidance $20-23M

## Summary
- Preliminary Q4 2021 revenue $3.6-$3.7M, up 71-77% YoY vs $2.1M.
- Full year 2021 revenue $13.0-$13.1M, up 113-116% from $6.1M in 2020.
- U.S. heart failure revenue $8.4M, Europe $3.9M, U.S. legacy $0.7M for 2021.
- Active implanting centers grew to 46 as of Dec 31, 2021 from 38 as of Sep 30, 2021.
- FY2022 revenue guidance $20-$23M; Q1 2022 expected $3.6-$4.0M.

## SEC filing metadata
- accession: 0001104659-22-002514
- form_type: 8-K
- ticker: CVRX
- cik: 0001235912
- company_name: CVRx, Inc.
- filed_at: 2022-01-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1235912/000110465922002514/0001104659-22-002514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1235912/000110465922002514/tm222384d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-002514
- JSON: https://secwatch.observer/filing/0001104659-22-002514.json
- Plain text: https://secwatch.observer/filing/0001104659-22-002514.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.